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Radiotherapy (XRT) delivered with the antibody cetuximab is a standard treatment option for squamous cell
carcinomas of head and neck (SCCNH). Cetuximab acts by blocking epidermal growth factor receptor (EGFR)
signaling to inhibit cancer progression. However, a significant percentage of patients will not respond to XRT and
cetuximab. Statins reduce the synthesis of cholesterol and isoprenoid derivates that may be required for efficient
EGFR signaling. We assessed whether the statin simvastatin could improve this combined therapy. In vitro,
simvastatin enhanced the effects of XRT alone and in combination with cetuximab in wound healing, cell
proliferation, and clonogenic assays in FaDu cells. These results were reflected in xenoimplanted tumors growing
into subcutaneous tissue of athymic mice where concomitant treatment with simvastatin decreased tumor
growth. Consistently, lower levels of phosphorylated extracellular signal–regulated kinases 1 and 2,
phosphatidylinositol 3-kinase/AKT–protein kinase B, and signal transducer and activator of transcription 3
oncoproteins and higher levels of caspase-3 and apoptosis in cell cultures and xenografts were observed. The
EGFR-overexpressing A431 cell line was used to reproduce these antitumor effects of simvastatin. Our findings
suggest that simvastatin may improve the efficiency of concomitant XRT and cetuximab. Further investigation in
the treatment of SCCNH is warranted.
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Radiotherapy (XRT) delivered concomitantly with monoclonal
antibody cetuximab (C225) is a standard treatment option for locally
advanced head and neck cancer [1,2]. C225 acts by binding to the
epidermal growth factor receptor (EGFR) to counteract downstream
signals that drive cancer cells' aberrant proliferation and resistance to
radiation-induced cell killing. However, although C225 leads to
improved clinical outcomes in many cases, it appears to be partially or
wholly inactive in others due to either intrinsic resistance or acquired
resistance to EGFR inhibition [3].
Statins act by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A
reductase, which reduces the synthesis rate of endogenous mevalo-
nate, a compound that is necessary for the biosynthesis of cholesterol
and isoprenoid derivates such as farnesyl and geranylgeranyl residues.
The addition of isoprenoid derivates (prenylation) to small GTP-binding proteins (e.g., RAS and RAS-homologous GTPases) is an
essential posttranslational modification for the normal activity of
these proteins. This prenylation allows the correct localization and
function of small GTP-binding proteins in the inner leaflet of the
plasma membrane [4]. In particular, the decreased farnesylation rate
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convey signals from growth factor receptors (including EGFR) to
downstream effectors, thus interfering with cell survival [5]. In
addition to decreasing protein prenylation, statins may also reduce
plasma membrane fluidity, particularly in cholesterol-rich rafts, thus
interfering with molecular interactions (receptor dimerization)
involved in cell signaling emission [6]. A mutated tumor-suppressor
protein p53 has been found to upregulate the mevalonate pathway, an
observation that suggests that statins may help revert the malignant
phenotype of p53-mutated cancer cells [7].
We hypothesized that the statin simvastatin would contribute to
C225 radiosensitization by weakening EGFR cell signaling, interfer-
ing with the repair of radiation-induced DNA damage and cell
proliferation. Simvastatin would participate in the cancer cell killing
due to XRT and C225 and eventually would improve tumor control.
The principal aim of our study was to preclinically evaluate whether
the addition of simvastatin could increase the antitumor effects of
concomitant XRT and C225 in xenografted tumors derived from
head and neck squamous carcinoma cells.
Materials and Methods
Cancer Cell Lines
Because in this work we explored EGFR inhibition by C225 in
head and neck cancer, our study was carried out with the FaDu cell
line, derived from a human squamous cell carcinoma of the
hypopharynx that overexpresses EGFR, a common trait of human
squamous cell carcinomas of head and neck (SCCHN). In addition,
we repeated most of the experiments using the EGFR-overexpressing
cell line A431 derived from a human vulvar squamous carcinoma,
which has been typically used to underpin the biology of treatment
with C225. Although these two cell lines are different in their origin,
they are, interestingly, highly dependent on EGFR [8], and
potentially sensitive to C225, and its modulation by simvastatin.
These cells were purchased from the American Type Cell Collection
(LGC Promochem, Barcelona, Spain) and were maintained under
standard cell culture conditions free of mycoplasma contamination.
FaDu and A431 cells are wild type according to the DNA
sequencing analysis we performed on codons 12 and 13 of exon 2 in
the KRAS gene.
XRT and Pharmacological Treatments
XRT was administered at room temperature using 6-MV X-rays at
a dose rate of 2.7 Gy/min from a Varian Clinac 2100 linear
accelerator. Mice received local irradiation as described elsewhere [9].
C225 (Merck, Darmstadt, Germany) was directly administered to cell
cultures at doses ranging from 10 to 30 nM and to mice at 1 mg/
mouse per week. Simvastatin was dissolved in DMSO for cell culture
experiments and used at doses ranging from 1 to 25 μM depending
on the type of experiment, while it was dissolved in 1,2-propanediol
in distilled water 1:1 (vol/vol) for animal treatments and used at a
fixed dose of 50 mg/kg per day (simvastatin, DMSO, and
propanediol were purchased from Sigma-Aldrich, St Louis, MO).
Drug doses were based on preliminary studies from our group and
previously published works [10–15]. We have varied doses and
timings to adapt them to the type of assay to examine the effect of
concomitancy between drugs for at least a period of 48 hours.
Equivalent mock irradiations and treatments with appropriate
vehicles were carried out as controls.Wound Healing Assay
FaDu cells were seeded in 60-mm dishes and cultured until
confluence. Then, the cell cultures were pretreated for 48 hours with
15 μM simvastatin, 30 nM C225, or 30 nM C225 plus 15 μM
simvastatin before being irradiated with 3-Gy dose. Immediately
thereafter, monolayers were scratched (three different locations per
dish) with a 200-μl pipette tip to simulate a wound and cultured in
the presence of the drugs. Distances between the wound margins were
measured at 0, 1, 2, 4, 8, and 24 hours under a Leica DMIL LED
light microscope with the Leica Application Suite LAS v.2.6 software
(Leica, Wetzlar, Germany).
Cell Proliferation Assay
A total of 300,000 cells were seeded in 60-mm dishes and cultured
for 3 days until semi-confluence. Then, corresponding cell cultures
were treated with 10 nM C225 for FaDu cells or 30 nM for A431
cells alone—in preliminary experiments, FaDu cells were found to be
more sensitive to C225 than A431 cells (data not shown)—or
combined with 15 μM simvastatin, both drugs added 2 hours before
XRT (3 Gy) and during the assays. The number of cells present in
the cell cultures was counted using a hemocytometer at 0, 24, 48,
and 72 hours.
Clonogenic Assay
Two thousand single cells were seeded in 60-mm dishes and
allowed to attach for 24 hours. Then, cell cultures were pretreated for
24 hours before XRT with 1 μM simvastatin alone, C225 alone (10
nM C225 for FaDu cells or 30 nM for A431 cells), or with the two
drugs. Next, cell cultures were either irradiated (2 Gy) or subjected to
mock irradiation in the presence or absence of the drugs. Colonies
were stained with crystal violet. Clonogenic cell survival was
calculated as the ratio between the number of colonies presented
after irradiation and the number of cells plated, which was then
normalized by the clonogenic efficiency of the untreated controls.
Note that when XRT was applied, clonogenic cell survival was the
survival after 2 Gy, which is the most useful clinical marker of
intrinsic radiosensitivity.
Xenografts and In Vivo Treatments
To generate tumor xenografts, 106 cells suspended in 100 μl of
medium were injected into subcutaneous tissues on the right hind
limb of 6- to 8-week-old female athymic Swiss nu/nu mice (Harlan,
Gannat, France). Cells were injected on a Monday and left to grow for
7 days, moment when the treatments began. Tumor growth was
measured—π/6 × (large diameter) × (small diameter)2—twice
weekly. Mice were killed when the tumor volume reached 1200
mm3, when the mice showed moderate to severe toxicities, or when
significant differences between groups were observed. All experimen-
tal procedures were approved by the Institutional Animal Care and
Ethics Committee.
The mice received fractionated XRT, C225, and simvastatin. XRT
was selectively delivered fromMonday to Friday for 2 weeks using the
6-MV X-ray beams at doses of 20 to 30 Gy depending on type of
experiment, in 10 fractions, 1 fraction each day. On the first day of
treatment, C225 was intraperitoneally injected 6 hours before
irradiation at doses of 1 mg per animal to allow the antibody to
have time to saturate the EGFR. Next, C225 was administered on
days 3, 7, and 10 at doses of 0.5 mg per animal 2 hours (together with
simvastatin or its vehicle) before irradiation as a maintenance C225
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for 12 days 2 hours before irradiation. Mice were randomly allocated
to receive XRT plus C225 or XRT, C225, and simvastatin as well as
to receive single treatments with XRT, C225, or simvastatin alone. In
addition, a group of mice treated in parallel was killed on day 4 to
obtain tumor samples for immunofluorescence.
Western Blot Analysis
Semi-confluent cell cultures were pretreated for 48 hours with
C225 and simvastatin in FBS-free medium and then irradiated with a
single dose of 5 Gy. Twenty minutes after irradiation, cell cultures
were rinsed in ice-cold phosphate-buffered saline (PBS) and lysed in
radioimmunoprecipitation assay buffer with protease and phospha-
tase inhibitors. Vehicle and mock irradiation were provided as
controls. Protein concentration in the lysates was determined by the
Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL).
Proteins (35 μg) were resolved in the SDS-PAGE system (Bio-Rad
Laboratories, Hercules, CA) and blotted onto Hybond nitrocellulose
membrane (GE Healthcare–Amersham Pharmacia Biotech, Buck-
inghamshire, United Kingdom). We used the following
primary antibodies: mouse anti-EGFR total at a 1:200 dilution,
rabbit anti–phosphorylated EGFR-Y1086 at a 1:1000 dilution,
mouse anti–phosphorylated extracellular signal–regulated kinases 1
and 2 (ERK1/2) at a 1:5000 dilution, and mouse anti–α-tubulin at
a 1:5000 dilution (all of the aforementioned antibodies were
purchased from Sigma-Aldrich); rabbit anti–phosphatidylinositol 3-
kinase/AKT–protein kinase B (AKT) total at a 1:500 dilution, rabbit
anti–phosphorylated AKT-S473 at a 1:500 dilution, rabbit anti–
signal transducer and activator of transcription 3 (STAT3) total at a
1:1000 dilution, rabbit anti–phosphorylated STAT3-Y705 at a
1:500 dilution, and anti–cleaved caspase-3 antibody at a 1:500
dilution, all from Cell Signaling Technology (Danvers, MA); rabbit
anti-ERK1/2 total [16]; rabbit anti–caspase-3 (Santa Cruz Biotech-
nology, Inc, Santa Cruz, CA) at a 1:1000 dilution. The nitrocellulose-
bound primary antibodies were incubated with anti-mouse IgG or
anti-rabbit IgG HRP-linked antibody (GE Healthcare) and were
detected by enhanced chemiluminescence staining ECL/ECL Plus
(GE Healthcare). Chemiluminescence staining was transformed to
arbitrary units of optical density using a digital imaging analysis system
(GelDoc 2000 and Quantity One software; Bio-Rad Laboratories),
and the results were represented on histograms.
Immunofluorescence for Cleaved Caspase-3
Cleavage of caspase-3, used as an apoptotic marker, was
determined by a standard immunofluorescence process on cells
cultured on sterilized coverslips and on 3-μm cryostat sections of theTable 1. Wound Healing Assays in FaDu Cell Line
Wound Size (Percentage of Healed Wound)
2 Hours 4 Hours
Nontreatment 5.80 ± 1.20 10.59 ± 1.68
XRT (3 Gy) 5.61 ± 0.87 9.09 ± 1.37
C225 (30 nM) 5.17 ± 1.15 7.83. ± 1.47
Simvastatin (15 μM) 2.04 ± 0.46 6.37 ± 1.73
XRT + C225 5.14 ± 1.05 8.93 ± 1.52
XRT + C225 + simvastatin 4.20 ± 0.80 6.98 ± 1.36
Cell cultures were treated as indicated in the Materials and Methods section. Values are means ± SE
treatments are the same as in the single treatments. P value (Mann-Whitney test): (1) compared to nxenografts scheduled on the fourth day of treatment. Regardless of the
origin, the samples were fixed, permeabilized (0.1% Triton in PBS for
10 minutes), and incubated for 1 hour with a protein-blocking
solution (20% goat and 20% horse sera in PBS). Next, the samples
were incubated overnight with a rabbit anti–cleaved caspase-3
monoclonal antibody (Cell Signaling Technology) at a 1:100 dilution
at 4°C. To detect primary antibodies, the samples were incubated
with a goat anti-rabbit Alexa Fluor 594 antibody (red fluorescence)
(Invitrogen, Carlsbad, CA) at a 1:200 dilution for 1 hour at room
temperature. Then, slices were mounted using Vectashield
(Vector Laboratories Inc, Burlingame, CA) mounting medium with
4′-6-diamidino-2-phenylindole DNA staining fluorochrome (blue
fluorescence). Fluorescence images were captured using a Nikon
Eclipse 80i epifluorescence microscope (Nikon Instruments, Kana-
gawa, Japan) and then analyzed with the Nis-Elements, Basic
Research (Nikon) software. The apoptosis index was calculated as the
ratio between red fluorescence (from detection of cleaved caspase-3)
and blue fluorescence from nuclei.
Statistics
Results were expressed as means ± SEM. Statistically significant
differences in between-group comparisons were defined by a two-
tailed significance level of P b .05 using the Mann-Whitney test. The
Statistical Package for Social Sciences, version 13.0 (IBM, Madrid,
Spain) was used for data analysis.
Results
Simvastatin Decreased Wound Healing, Cell
Proliferation, and Clonogenic Survival of Cells Treated
with XRT and Cetuximab
The principal aim of this study was to test whether simvastatin may
increase the therapeutic effect of XRT and C225 on tumor growth in
xenograft models derived from human squamous cell carcinomas. In
the first instance, an in vitro approach was undertaken to evaluate
whether this statin could influence cell viability of cell cultures treated
with XRT and C225. The range of doses for XRT (single dose of 2-3
Gy) and for C225 (10-30 nM) that were used in this study were based
on previous reports [13,15], whereas the dose for simvastatin was
based on dose-response preliminary results (data not shown), and data
from the literature [11], and varied according to the length of each
assay. We examined immediate effects of treatments by means of
wound healing assay in FaDu cell line. Wound size decreased
progressively, as wounds were repaired, over a 24-hour period. All
treatments slowed down wound healing, but the rate of healing was
lower in cultures that received simvastatin (Table 1). At 2, 4, and8 Hours 24 Hours P Value at 24 Hours
15.55 ± 1.85 36.80 ± 3.23
13.11 ± 2.16 25.27 ± 2.19 .077 (1)
11.07 ± 2.15 18.78 ± 3.55 .001 (1)
9.32 ± 1.52 12.75 ± 2.37 .001 (1)
12.46 ± 1.73 21.66 ± 2.35 .001 (1)
9.43 ± 1.58 12.36 ± 1.78 .001 (1)
.005 (2)
of three independent experiments, with each experiment duplicated. Doses used in the combined
ontreatment condition and (2) compared to XRT + C225.
Table 3. Clonogenic Assays in FaDu and A431 Cell Lines
Clonogenic Cell Survival (%)
Drugs for 14 Days P Value Drugs for 48 Hours P Value
FaDu cell line
Nontreatment 100 ± 0.00 – 100 ± 0.00 –
XRT (2 Gy) 71.7 ± 1.37 .002 (1) 80.6 ± 3.47 .002 (1)
C225 (10 nM) 28.2 ± 1.92 .002 (1) 33.1 ± 1.31 .002 (1)
Simvastatin (1 μM) 93.1 ± 2.01 .040 (1) 87.3 ± 3.48 .040 (1)
XRT + simvastatin 69.7 ± 1.88 .002 (1) 62.1 ± 3.15 .002 (1)
C225 + simvastatin 23.0 ± 2.20 .002 (1) 68.0 ± 6.46 .002 (1)
XRT + C225 22.4 ± 1.76 .002 (1) 47.1 ± 1.78 .002 (1)
XRT + C225 + simvastatin 13.0 ± 2.11 .002 (1) 33.0 ± 1.05 .002 (1)
.004 (2) .004 (2)
A431 cell line
Nontreatment 100 ± 0.00 – 100 ± 0.00 –
XRT (2 Gy) 78.5 ± 2.57 .001 (1) 89.8 ± 0.84 .037 (1)
C225 (30 nM) 74.3 ± 4.09 .001 (1) 88.5 ± 1.02 .037 (1)
Simvastatin (1 μM) 75.6 ± 3.47 .001 (1) 87.5 ± 1.30 .037 (1)
XRT + simvastatin 64.7 ± 2.21 .001 (1) 90.1 ± 1.95 .037 (1)
C225 + simvastatin 62.5 ± 3.50 .001 (1) 93.7 ± 0.52 .037 (1)
XRT + C225 58.0 ± 3.46 .001 (1) 92.5 ± 1.14 .037 (1)
XRT + C225 + simvastatin 44.7 ± 4.27 .001 (1) 76.9 ± 3.63 .037 (1)
.009 (2) .050 (2)
Cell cultures were treated as indicated in the Materials and Methods section. Values are means ± SE.
For FaDu and A431 cells, two and four independent experiments, with each experiment duplicated,
were performed for 14-day and 48-hour schemes, respectively. Doses used in the combined
treatments are the same as in the single treatments. P value (Mann-Whitney test): (1) compared to
nontreatment condition and (2) compared to XRT + C225 without simvastatin.
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simvastatin was involved in the higher inhibitory effects of the
treatments, although differences were not significant. However, when
the observation was extended to 24 hours, differences became more
apparent and statistically significant, suggesting that inhibition of cell
proliferation rather than cell migration—the latter being an early
event—could have been implicated in this observation. It is
important to note that triple treatment with XRT, C225, and
simvastatin was more cytotoxic than XRT and C225 without the
statin, which indicates a potential role for simvastatin (Table 1).
To investigate the effects of simvastatin on cell proliferation in
FaDu cells, as well as in A431 cells, we subjected cell cultures to the
different treatments for longer periods of time of 24, 48, and 72 hours
(Table 2). In both cell lines, cell number increased as a function of
time, but FaDu cells showed higher proliferation rates. Likewise, in
both cell types, cell proliferation was inhibited by all the therapeutic
schemes, an effect that was more obvious as time increased. For
individual treatments, XRT and simvastatin alone had the highest
effect. Regarding combined treatments, it is of note that the addition
of C225 to XRT was not reflected in a significant decrease of
proliferation although these cells were sensitive to C225 alone. On
the contrary, we found that the addition of simvastatin to XRT plus
C225 effectively resulted in a significant inhibition of proliferation,
leading at 72 hours to a decrease of 2.7-fold for FaDu cells and 5.5-
fold for A431 cells compared to XRT alone and 1.93-fold and 4.3-
fold, respectively, compared to XRT and C225 (Table 2).
Interestingly, the effect of C225 and simvastatin on proliferation
was smaller than the effect of XRT, C225, and simvastatin together,
in particular at 72 hours after the beginning of treatments. These
observations suggest that C225 and simvastatin in collaboration
may contribute to weaken cell recovery from XRT resulting in
higher cell killing.
To further verify and extend the results of these wound healing and
cell proliferation assays, the effect of treatments on clonogenic cell
survival was evaluated (Table 3). All conditions were evaluated by
performing assays under two types of drug exposures in combinationTable 2. Cell Proliferation Assays in FaDu and A431 Cell Lines
Cell Number (106)
24 Hours P Value
FaDu cell line
Nontreatment 2.63 ± 0.24 –
XRT (3 Gy) 1.46 ± 0.50 .062 (1)
C225 (10 nM) 2.32 ± 0.14 .156 (1)
Simvastatin (15 μM) 2.34 ± 0.60 .497 (1)
C225 + simvastatin 1.24 ± 0.29 .027 (1)
XRT + C225 2.11 ± 0.11 .093 (1)
XRT + C225 + simvastatin 1.97 ± 0.11 .071 (1)
.631 (2)
A431 cell line
Nontreatment 1.89 ± 0.33 –
XRT (3 Gy) 1.18 ± 0.07 .136 (1)
C225 (30 nM) 0.81 ± 0.02 .011 (1)
Simvastatin (15 μM) 1.49 ± 0.07 .497 (1)
C225 + simvastatin 1.01 ± 0.03 .011 (1)
XRT + C225 1.29 ± 0.19 .055 (1)
XRT + C225 + simvastatin 0.92 ± 0.03 .004 (1)
.150 (2)
Cell cultures were treated as indicated in the Materials and Methods section. Values are means ± SE
treatments are the same as in the single treatments. P value (Mann-Whitney test): (1) compared to nwith the same type of irradiation and period of colony formation:
drug exposure maintained for 14 days or drug exposure for only 48
hours (24 hours pre-XRT and 24 hours post-XRT). These two
different strategies were aimed to discriminate a possible effect of
drugs on cell proliferation from an early clonogenic cell killing effect,
which can be properly assessed without the presence of drugs during
the complete period of colony formation. We observed that the effect
of drugs was dependent on duration of exposure. The baseline plating
efficiency for FaDu and A431 cells were comparable, 16.76 ± 2.48%
and 14.29 ± 0.63%, respectively (Table 3). Regarding single
treatments, FaDu cells displayed higher radiosensitivity than A43148 Hours P Value 72 Hours P Value
4.39 ± 0.35 – 5.88 ± 0.55 –
2.36 ± 0.26 .007 (1) 2.93 ± 0.33 .017 (1)
3.48 ± 0.34 .121 (1) 4.26 ± 0.28 .071 (1)
3.05 ± 0.35 .042 (1) 3.09 ± 0.42 .017 (1)
1.63 ± 0.31 .007 (1) 2.02 ± 0.50 .007 (1)
2.62 ± 0.12 .003 (1) 2.94 ± 0.08 .002 (1)
2.10 ± 0.14 .002 (1) 1.52 ± 0.09 .002 (1)
.025 (2) .004 (2)
2.19 ± 0.15 – 2.97 ± 0.38 –
1.56 ± 0.04 .010 (1) 0.95 ± 0.04 .010 (1)
1.35 ± 0.07 .010 (1) 1.28 ± 0.09 .010 (1)
1.14 ± 0.06 .010 (1) 0.92 ± 0.03 .010 (1)
0.53 ± 0.06 .010 (1) 0.42 ± 0.04 .010 (1)
1.07 ± 0.14 .004 (1) 0.98 ± 0.19 .006 (1)
0.34 ± 0.07 .004 (1) 0.23 ± 0.08 .004 (1)
.004 (2) .004 (2)
of three independent experiments, with each experiment duplicated. Doses used in the combined
ontreatment condition and (2) compared to XRT + C225 without simvastatin.
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One micromolar simvastatin was definitely less effective than the
doses of simvastatin used in wound healing and proliferation assays.
However, it is interesting to note that simvastatin administered at a
dose of 1 μM (as used in the clonogenic assays) is closer to blood levels
of simvastatin that were achieved in clinical settings [17]. However,
higher doses of simvastatin precluded colony growth at all, because
zero colonies grew. With respect to the effect of drugs on XRT, the
addition of simvastatin enhanced radiation cell killing as reported by
others [14], although in FaDu and A431 cells our findings were not
consistent regarding duration of simvastatin exposure (Table 3). The
addition of C225 also enhanced the effect of XRT alone as described
previously in SCCHN [18]. In FaDu cells, clonogenic survival was
dramatically decreased by C225, whereas it was moderately
diminished in A431 cells (Table 3).
As our objective was to evaluate the role of simvastatin in XRT
treatment combined with C225, it was interesting to observe that
triple combination including simvastatin had the most inhibitory
effect on clonogenic survival in both cell lines irrespectively of the fact
that the drugs were applied for 14 days or for 48 hours. Triple
treatment augmented XRT alone cell killing by a factor of 5.5 (71.7%
vs 13.0%) and 2.4 (80.6% vs 33.0%), respectively, for FaDu cells and
1.75 (78.5% vs 44.7%) and 1.16 (89.8% vs 76.9%), respectively, for
A431 cells. Second, and more importantly, the impact of simvastatin
on the triple treatment was clearly significant as indicated by the
outcomes showing decreases in clonogenic survival by a factor of 1.72
(22.4% vs 13.0%) and 1.42 (47.1% vs 33%), respectively, for FaDu
cells and 1.3 (58.0% vs 44.7%) and 1.2 (92.5% vs 76.9%),
respectively, for A431 cells compared to double treatment of XRT
with C225 (Table 3). Moreover, in both cell lines, double treatment
with 48-hour C225 exposure was less effective than C225 alone, an
observation that suggests the participation of an early acceleration of
cell proliferation, a radiation-induced reaction already described in
A431 cell line by Schmidt-Ullrich and co-workers [19]. Interestingly,
this possible adaptive response was not observed after the triple
treatment, perhaps counteracted by simvastatin (Table 3). TakenFigure 1. Effect of simvastatin on the growth of FaDu xenografts treate
Gy), C225, or simvastatin as single treatments (A) or XRT (30 Gy) plus
the Materials and Methods section. Values are the means ± SE of
calculated by Mann-Whitney test. *P b .05 compared to nontreatmetogether, the in vitro results suggest that simvastatin could decrease
cell proliferation in combination with XRT and C225, being its effect
potentiated in long-term drug exposures, and provide new insights
about the triple combination.
Simvastatin Slowed the Growth of Xenografts Treated
with XRT and Cetuximab
Because of preliminary in vitro findings indicating a possible
activity of simvastatin as cell proliferation inhibitor in combination
with C225 and XRT, this study was continued to investigate
simvastatin role in xenografts. In tumors derived from FaDu and
A431 cell lines, single treatment with simvastatin alone had no effect
on tumor growth. On the contrary, treatment with C225 or XRT
significantly reduced tumor growth compared to untreated tumors,
XRT being the most effective treatment (Figures 1A and 2A). FaDu
tumors were more sensitive to XRT and C225 than A431 ones as was
also seen in clonogenic assays (Table 3).
To focus on the main interest of this study, we started experiments
irradiating FaDu tumors with 3 Gy per day for 10 days in
combination with C225 in the presence or absence of simvastatin.
Irrespectively of simvastatin, XRT plus C225 induced a transitory
complete regression of tumors that lasted around 7 days (Figure 1B).
After that, tumor growth rebounded but showed lower rates of
regrowth when the animals received simvastatin. The time that the
tumors took to achieve the size they had at the start of the treatment
experienced a considerable delay when simvastatin was added to
XRT + C225. The delay in mice that received simvastatin was 46 ±
5.8 days compared to 29 ± 3.2 days in the absence of simvastatin
(a difference of 17 days; P value = .065). From the start of XRT, the
time for the tumor volume to triple in size was 53.7 ± 4.4 days
versus 42.8 ± 1.4 days depending on the presence of simvastatin
or not, respectively (a difference of 11 days; P value = .086).
In A431-tumors, to prevent a complete response, XRT dose was
lowered to 2 Gy per day for 10 days. Contrary to the FaDu
xenografts, A431 tumors did not achieve a complete disappearance,
but similarly it was found that the mice treated with simvastatindwith radiation (XRT) and cetuximab (C225). Mice received XRT (30
C225 or XRT (30 Gy) plus C225 plus simvastatin (B), as specified in
five tumors per group (unless otherwise specified). P values were
nt group in A or XRT + C225 without simvastatin group in B.
Figure 2. Effect of simvastatin on the growth of A431 xenografts treated with radiation (XRT) and cetuximab (C225). Mice received XRT (30
Gy), C225, or simvastatin as single treatments (A) or XRT (20 Gy) plus C225 or XRT (20 Gy) plus C225 plus simvastatin (B), as specified in
the Materials and Methods section. Values are the means ± SE of five tumors per group. P values were calculated by Mann-Whitney test.
*P b .05 compared to nontreatment group in A or XRT + C225 without simvastatin group in B.
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Consistently with a simvastatin-induced enhancement in tumor
growth inhibition, the growth delay after irradiation for the tumors
treated with simvastatin was 14.4 ± 5.9 days in contrast with the mice
that did not receive an additional dose of simvastatin, in which tumor
size never decreased below the size the tumors had at the time of
irradiation (P value = .081). In these mice, the time to triplicate the
initial tumor volume was increased if they received simvastatin from
47 ± 15.2 to 60 ± 6 days (a difference of 13 days; P value = .539).
Although these experiments were not statistically significant, they
were suggestive of an antitumor effect, in line with the results we
observed for FaDu tumors. Regarding animals' global health status,
no differences were observed in between groups related to mouse
weight and physical or clinical appearance.Figure 3. Effect of the addition of simvastatin to XRT and C225 on th
C225 and 5, 15, or 25 μM simvastatin in FBS-free medium, FaDu cell
analysis was used to determine the levels of proteins as it is shown. α
quantifications (in arbitrary units) of the protein levels are indicated as
independent lysates, each blotted in triplicate, were used. *P b .05 cBecause in vivo, and in vitro, findings were compatible with the
notion that simvastatin could enhance the antitumor effect of XRT
and C225 in FaDu and A431 cell–derived tumors, we decided to
evaluate if simvastatin could have a negative influence on the biology
of these tumors.
Simvastatin Induced Apoptosis after XRT plus Cetuximab
We hypothesized that the effect of simvastatin might be related to
apoptosis activation. To evaluate this possibility, we determined the
cleaved caspase-3, a surrogate marker that indicates irreversible cell
death through apoptosis. In cultured cells, we found that levels of
cleaved caspase-3 increased in simvastatin-treated cells in a dose-
dependent manner, while the levels of pro-caspase-3 remained
unchanged (Figure 3). To validate these in vitro findings and establishe cleaved caspase-3. After a 48-hour period of exposure to 10 nM
s were irradiated with a dose of 5 Gy as indicated. (A) Western blot
-Tubulin was included as a loading control. (B) Optical densitometry
fold relative to the XRT + C225 condition; bars show SEM. Three
ompared to XRT plus C225 without simvastatin.
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cells treated with XRT and C225, xenograft tumors were sampled
as previously described. Although the tumors received only 3 days
of treatment and the percentages of apoptotic cells were relatively
low, we already found that the number of cleaved caspase-3–
positive cells was significantly higher in FaDu-derived tumors
treated with triple treatment at this time point (1.99 ± 0.20% vs
5.96 ± 0.56%; P = .0001; Figure 4A). The same observation wasFigure 4. Simvastatin was associated with apoptosis in xenografts
simvastatin as described in Figure 1. Tumors were extirpated on the fo
showing cleaved caspase-3 (red fluorescence) and cell nucleus (blue f
Columns show the mean values and bars show the SEM of apoptotic
microscopic images were analyzed per slice. On average, 200 cells w
experiments from each treatment scheme. *P b .05 compared to XRmade in A431-derived tumors (4.40 ± 0.62% vs 8.83 ± 1.46%; P =
.005; Figure 4B).
Simvastatin Interfered with Oncogenic Signaling
Pathways in Cells Treated with XRT and Cetuximab
We also investigated whether simvastatin could affect crucial
cellular signaling pathways involved in the malignant phenotype of
cancers. We found that the ionizing radiation elicited the. Mice were treated with XRT and C225 or with XRT, C225, and
urth day, 24 hours after the last treatment. Representative pictures
luorescence) are shown for FaDu- (A) and A431-derived (B) tumors.
cells relative to the total number of cells. Six randomly selected field
ere counted per field. Data were obtained from two independent
T plus C225.
Figure 5. Effects of simvastatin on the levels of phosphorylated ERK, AKT, and STAT3. FaDu cells were treated with XRT, C225, and
simvastatin as described in Figure 3. (A) Western blot analysis was used to determine the levels of proteins as it is shown. α-Tubulin was
included as a loading control. (B) Optical densitometry quantifications (in arbitrary units) of the protein levels are indicated as fold relative
to the XRT + C225 condition; bars show SEM. Three independent lysates, each blotted in triplicate, were used. *P b .05 compared to XRT
plus C225 without simvastatin.
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of simvastatin to XRT did not modify phosphorylated levels of EGFR
(Figure 5). In contrast, C225 had an inhibitory effect on the
radiation-induced phosphorylation of EGFR, which was neither
changed in the presence of simvastatin, indicating that simvastatin
had little effect on EGFR (at least on phosphorylated tyrosine 1086).
Although simvastatin was inactive on EGFR, we observed a
noticeable reduction of the phosphorylation of ERK1/2. Simvastatin
has a weak effect on the activation of phosphorylated AKT and
phosphorylated STAT3 and lacked of a dose-response inhibitory
effect compared to ERK1/2 protein. No effect on the levels of total
EGFR, ERK1/2, AKT, and STAT3 were found (Figure 5).
Discussion
In this study, we preclinically explored whether a treatment regime
involving the addition of simvastatin to XRT and C225 merits further
research. Given the fact that XRT and concurrent C225 is a common
treatment for locally advanced SCCHN, we believe that this is a
relevant question. Although early time points explored in scratch and
proliferation assays did not provide a clear clue on the effectiveness of
simvastatin, it was shown that the addition of simvastatin for 48 hours
or more significantly decreased proliferation and clonogenic survival of
cells treated with XRT and C225. Moreover, we used an experimental
model with tumor cells derived from squamous cell carcinoma of the
hypopharynx that suggests that simvastatin may increase the
antitumor effect of XRT plus C225—at doses and fractions of XRT
that mimic doses administered in the clinical setting. The effects of
simvastatin were recapitulated using A431 cell line validating the
notion that simvastatin may have a role in combination with XRT and
C225. The addition of simvastatin was associated with an increase in
apoptosis and a decrease in the levels of activated ERK1/2, AKT, and
STAT3 oncoproteins, a set of observations that provide support to the
higher antitumor effects produced by the triple treatment.
The role of statins in cancer therapy has been reviewed previously
elsewhere [17,20–22]. In noncancerous tissues, statins reduce theproliferation of the atherosclerotic plaque and the chronic inflamma-
tory process associated with atheromatosis [23]. Similarly, simvastatin
represses the proliferation of glomerular mesangial cells, suggesting a
preventive role in diabetic nephropathy, an effect mediated by its
interference with isoprenylation of small GTP-binding proteins [24].
In addition to the antiproliferative and anti-inflammatory properties
of statins in non-neoplastic tissues, increasing evidence supports a role
for statins in cancer through the inhibition of cancer cell proliferation,
angiogenesis, and metastatic potential. These effects have been proven
in numerous different cell lines derived from myeloid and
lymphoblastic leukemia, neuroblastoma, rhabdomyosarcoma, medul-
loblastoma squamous cell carcinoma of the cervix, melanoma, high-
grade glioma, and cancer of the kidney, testis, breast, stomach,
prostate, and small cell lung cancer [11,25-27]. Published data
indicate that statins can sensitize cancer cells to chemical drugs such as
doxorubicin, nitrosourea, cisplatin, and 5-fluorouracil [28,29].
Recently, it was reported that the combination of simvastatin and
C225 sensitize colon cancer cells bearing RAS mutations [12]. In
combination with XRT, the statin lovastatin has also been found to
have a radiosensitizing effect in lung cancer and osteosarcoma cell lines
that express mutated RAS [14,30]. Interestingly, several randomized
controlled trials and case-control studies have found that statins used
to lower cholesterol levels may exert a protective effect against cancer
[31–33]. In addition, a recent epidemiological study found evidence
suggesting that statin use can reduce cancer-related mortality [34]. A
number of clinical trials have investigated the antitumor effect of
statins. In one trial, the combination of 5-fluorouracil and the statin
pravastatin was associated with a higher tumor response and better
survival than chemotherapy alone in patients with unresectable
hepatocarcinoma [35]. Similarly, a review carried out by Hindler et al.
described the promising results for statin use in SCCHN and other
types of cancer [21].
To our knowledge, this is the first in vivo study of combined XRT,
C225, and statins in an experimental model that suggests that
simvastatin may increase antitumor effects, providing new
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radiation oncology. The results from tumor growth and cell death
analysis of tumor samples from the two cell lines give support to the
increased antitumor effect of triple combination. The findings we
report are consistent with the mechanism of anticancer action of
simvastatin described previously as monotherapy or in combination
with radiation or classic chemotherapies. However, this is the first
report in which simvastatin has been successfully assessed in
combination with an anti-EGFR therapy using xenoimplanted
tumors. We have observed that statins have antiproliferative effects
[20,22] and that they can contribute to cancer cell killing by
apoptosis [11,12,14,27]. We have also observed that the levels of
ERK1/2, AKT, and STAT3 proteins that promote cancer
progression were reduced by simvastatin, a finding that correlated
with a loss of cell viability and with apoptosis. In addition to
increasing apoptosis, this decrease in activated ERK1/2, AKT, and
STAT3 levels—oncoproteins known to have a role in repairing
radiation-induced damage and in promoting the development of
aggressive malignant phenotypes [13,15,36]—could impair the
ability of cancer cells to recover from XRT and C225.
We believe that the evidence in the present report warrants further
clinical investigation, although we have to add some comments that
deserve a particular mention. We and others have found significant
antitumor activity at concentration levels ranging from 1 to 25 μM.
However, the typical plasma levels to treat hypercholesterolemia are
approximately 10 times lower [37]. This observation raises additional
concerns about statin-induced liver and muscle toxicity, especially
given that only a few clinical trials have been carried out to address
this issue. One phase I trial in patients with SCCHN established that
7.5 mg/kg per day of lovastatin for 2 weeks (the dose for dyslipidemia
is 1 mg/kg per day) followed by a 1-week break was a well-tolerated
scheme (provided that creatinine clearance is N70 ml/min) [38].
Nevertheless, lovastatin doses can be safely escalated (35 mg/kg per
day) as long as ubiquinone (co-enzyme Q) is given concomitantly
[37,39]. The existing uncertainties about the effective dose of statins
in cancer therapy are aggravated by the fact that lovastatin and
simvastatin are administered as inactive prodrugs and need to be
enzymatically activated to β-hydroxy acid by esterase and paraox-
onase-mediated hydrolysis [40]. To our knowledge, no published
studies have measured the actual active acid form of simvastatin or
lovastatin in cell cultures and/or in mice—in which liver statins
undergo active transformation—to properly infer the statin dose that
should be used in clinical cancer trials. Although clinical and
epidemiological data suggest that relative low plasma concentrations
of statins could be sufficient to achieve an antitumor effect,
reasonably, new phase I trials with pharmacokinetic and pharmaco-
dynamic studies are warranted.
In conclusion, we have presented a proof-of-concept study that
demonstrates that simvastatin may enhance antitumor response of
concomitant XRT and C225. In this preclinical work, we have
provided evidence that supports further basic and clinical investiga-
tion of simvastatin in SCCHN disease.
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